MGH Center for Women's Mental Health https://validator.w3.org/feed/docs/rss2.html Welcome to the MGH Center for Women’s Mental Health Rapid Symptom Relief in Postpartum Psychosis with Brexanolone Is There a Link Between Endometriosis and Perinatal Depression? Collective Members Sleep Awareness Week: What You Should Know About Sleep and Perinatal Mental Health Introducing Members of The 2026 Psychiatry Collective Don’t Forget About Brexanolone’s Little Sister: Zuranolone The National Pregnancy Registry for ADHD Medications The National Pregnancy Registry for Sedative-Hypnotics and Other Sleep Medications National Pregnancy Registry for Antidepressants National Pregnancy Registry for Atypical Antipsychotics National Pregnancy Registry for Psychiatric Medications © Topiramate and Risk of Major Malformations: What Clinicians and Patients Need to Know Bringing More Than Blue Documentary Across The Globe Postpartum Depression with Comorbid Anxiety: Optimizing Treatment Development of Zuranolone (SAGE 217) for PPD Will Move Forward More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression Essential Reads: Zuranolone for Postpartum Depression PMDD Treatment with Serotonin Reuptake Inhibitors: Neuroactive Steroids and GABA May Play a Role NPR’s 1A Live Discusses Perinatal Depression and the New Medication Zuranolone Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application for Zuranolone to the FDA in 2022 Can Esketamine Be Used to Prevent Postpartum Depression? Zuranolone for Postpartum Depression: Results from the SKYLARK Study Harnessing the Power of Peer-Delivered Interventions for Perinatal Mood and Anxiety Disorders Beyond the EPDS: Using AI to Identify Women at Risk for Postpartum Depression Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval More Data on Zuranolone for Postpartum Depression: When Will It Hit the Market? FDA Approves Zuranolone for the Treatment of Postpartum Depression Zuranolone: A novel postpartum depression treatment, with lingering questions New Oral Drug Zuranolone (Zurzuvae) for Postpartum Depression is Now Available Your Patient Has Postpartum Depression: Do You Use Zuranolone or a Traditional Antidepressant? Telehealth Group Prenatal Care: Expanding Access and Connection to Pregnant Patients The Complex Motives Behind Cannabis Use During Pregnancy Weekly Roundup for March 6, 2026: Recent Publications in Women’s Mental Health Weekly Roundup for February 20, 2026: Recent Publications in Women’s Mental Health For International Women’s Day, Take Action to Improve Maternal Mental Health Weekly Roundup for March 13, 2026: Recent Publications in Women’s Mental Health Intervention Implementation for Hot Flashes and Depression in Black Women Improved Mental Health Outcomes Associated with Doula Support: A Review of the Evidence For Women with Bipolar Disorder: Sleep Disruption May Increase Risk of Postpartum Psychosis Weekly Roundup February 13, 2026: AI and Apps for Perinatal Depression, Pregnancy and Postpartum Sleep, Dobbs Fallout, and More Clinical Update 2026: Z-Drugs and Pregnancy Fact Sheet: Valproic Acid (Depakote) and Pregnancy On-Demand Courses (For Providers) Educational Program On-Demand Courses Educational Program OLD Announcing our 2026 Inaugural NP Masterclass Cohort Sleep Problems During Pregnancy: Screening and Opportunities for Intervention Zuranolone Improves Anxiety Symptoms and Insomnia in Women with Postpartum Depression